STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill.
A new pill designed to mimic the effects of exercise has shown promising early results in maintaining weight loss and muscle mass, according to Enveda, a biotech company based in Colorado. The drug, ENV-308, works by suppressing appetite and preserving lean muscle mass, addressing a common issue with GLP-1 drugs where patients often lose muscle as they lose weight.
Enveda's drug candidate, lac-phe, was discovered by Stanford scientists and shown to suppress appetite and reduce obesity in animals in a 2022 Nature paper. If successful in clinical trials, ENV-308 would be the first "leptin sensitizer in a pill."
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
